Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 12, 2005

View Archived Issues

Mechanisms underlying SERP-1 mediated inhibition of monocytic adhesion and migration

Preclinical efficacy of GRN-163 in lung cancer

Liposomal encapsulation improves dexamethasone's profile

Novel highly potent and selective TACE inhibitor disclosed

Tesaglitazar reduces the incidence of metabolic syndrome in hypertriglyceridemic patients

Avalon submits IND for AVN-944 for cancer

Anturol begins phase II study for overactive bladder syndrome

Intrac changes name to Javelin Pharmaceuticals

IPdR enters phase I cancer study

GlaxoSmithKline to acquire ID Biomedical

IND approved for clinical testing of Elacyt for cancer

Ardana holds pre-IND meeting for Teverelix LA

Xcytrin studied for second-line treatment of recurrent metastatic NSCLC

CE Mark approval for Taxus Liberte stent

BMS-740808: A novel factor Xa inhibitor with in vivo efficacy and good PK profile

Lateral hypothalamus orexin neurons: new targets for addiction

Exubera recommended for approval

Novel SARMs developed by Bristol-Myers Squibb

New therapeutic agents for cancer disclosed in recent patents

KSP inhibitor blocks tumor growth in mice

Update on darifenacin in overactive bladder

New data on the antiarrhythmic activity of AZD-7009

Astellas Pharma discloses novel therapeutic agents for bone disorders

Sorafenib submitted for European approval for advanced kidney cancer

FDA advisory committee votes to recommend Pargluva for type 2 diabetes

Biovail receives FDA approval for once-daily tramadol

New agents for treating hepatitis C infection disclosed by Japan Tobacco

Immunosuppressant S1P1 receptor agonists prepared and tested at Merck & Co.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...